title: Successful treatment with liposteroid followed by reduced intensity stem cell transplantation in an infant with perforin deficiency presenting with hemophagocytic lymphohistiocytosis.
abstract: Perforin deficiency characterized by markedly reduced cytotoxic T and natural killer cell activities is one type of familial hemophagocytic lymphohistiocytosis (FHL). FHL is a fatal inherited disease, and treatment with stem cell transplantation has resulted in a normal activity of killer cells. We herein report a case of FHL with perforin deficiency that was primarily treated by the administration of liposteroid to reduce hypercytokinemia. Thereafter, allogenic bone marrow transplantation with nonmyeloablative conditioning was successfully performed without any adverse effects on the patient's physical or developmental status. These observations suggest that this treatment strategy might thus be recommended in infants with FHL to reduce treatment-related complications, especially in patients with relatively mild clinical courses.
authors.affiliation: Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Hussam Mahmood
authors.initials: HM
authors.lastname: Salih
authors.forename: Teruyuki
authors.initials: T
authors.lastname: Kajiume
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nakamura
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Miyagawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Sato
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nishimura
authors.forename: Masao
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D003907:Dexamethasone / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D051359:Lymphohistiocytosis, Hemophagocytic / Q000235:genetics / Q000628:therapy*; D008562:Membrane Glycoproteins / Q000032:analysis / Q000172:deficiency* / Q000235:genetics; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins / Q000032:analysis / Q000172:deficiency* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D008562:Membrane Glycoproteins; D052899:Pore Forming Cytotoxic Proteins; D054353:Perforin; C035081:dexamethasone 21-palmitate; D003907:Dexamethasone